
















Mobile health for walking on the tightrope of
optimal physical activity to reduce the risk of
atrial fibrillation
Renate B. Schnabel 1,2*, Larissa Fabritz 1,3,4, and Paulus Kirchhof 1,2,3
1Department of Cardiology, University Heart and Vascular Center Hamburg Eppendorf, Hamburg, Germany; 2German Center for Cardiovascular Research (DZHK) partner site
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This editorial refers to ‘Accelerometer-derived physical activity and risk of atrial fibrillation’, by S. Khurshid et al.,
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Risk factor and lifestyle optimization has public health relevance for
the prevention of atrial fibrillation (AF) due to the high number of
affected individuals and the high morbidity and mortality of the dis-
ease. In this context, the relationship between physical activity and
AF has been of interest for a long time, but the potential benefit and
harm derived from different levels of regular physical activity are still
largely unknown. Extreme physical activity increases the risk for AF in
endurance athletes. Among long-distance cross-country skiers who
completed the Vasaloppet 90 km competition, those who partici-
pated repeatedly had the highest long-term AF incidence.1 Several
adaptions of the athlete’s heart observed in men and animal models
have been reported in relation to the risk of AF, such as larger hearts
with increased volume load and stretch, in particular of the atria,
enhanced vagal tone, sinus node impairment, bradycardia, atrial fibro-
sis, and inflammation.2
Moderate physical activity, in contrast, appears to be associated
with a lower risk of AF and is recommended for the prevention of
AF.3,4 The effects of low to moderate regular exercise in the popula-
tion are difficult to differentiate from the potential effects of lifestyle
and other correlated cardiovascular risk factors such as obesity.
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Graphical Abstract Overview of the potential role of mobile health applications and wearables for (big) data collection in research and im-
provement of lifestyle and risk factors through monitoring, quantification, and direct feedback to the user according to individualized targets. As an
example, a hypothetical graph for physical activity is shown with a U-shaped association.
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Immobility reflects comorbidities such as heart failure and sleep ap-
noea, as well as frailty, and may thus be a marker of increased risk of
developing AF. However, there are direct effects, too. In patients
with a body mass index >_27 kg/m2 and manifest AF, an increase in
cardiorespiratory fitness >_2 metabolic equivalents (METs) was
related to a lower recurrence of AF after 5 years in a risk factor man-
agement programme.5
Understanding the U-shaped relationship between physical activity
and AF risk has been a challenge. A hurdle was, until now, the correct
quantification of physical activity in populations. Self-reported activity
estimates are known to be unreliable. A recent meta-analysis that
normalized physical activity to the MET of tasks reported that guide-
line-recommended levels are associated with a significantly lower AF
risk, with remaining uncertainty with regard to the effect of very high
physical activity.6 Frequency of physical activity, e.g. number of days
per week, duration of exercise periods, and intensity certainly play a
role. In addition, temporal and intensity patterns of physical activity
are highly likely to alter their cardiovascular effects.
Quantifying physical activity
objectively
In this issue of the European Heart Journal, Khurshid and colleagues
finally overcome the imprecision of prior studies: They identified
>90 000 individuals in the UK Biobank with analysable data from
wrist accelerometers worn over 1 week. 7 The study provides a step-
change in our understanding of the relationship between physical
activity and AF. It also illustrates the power of open access to data
pursued by the UK Biobank.
The analysis by Khurshid et al. confirms that physical activity
approximating the threshold of moderate to vigorous physical activ-
ity, recommended by cardiac societies and the World Health
Organization, is associated with reduced AF risk. Longer periods of
more intensive physical activity were associated with incident AF and
stroke over a 5-year follow-up. Not unexpectedly, the agreement be-
tween the objectively quantified physical activity and self-reported
physical activity collected using the international physical activity
questionnaire was weak. The self-reported physical activity was not
significantly associated with either AF or stroke in the subsample
with physical activity measurements, although in the >400 000 indi-
viduals from the overall UK Biobank the association reached statistic-
al significance for AF.8 The current analysis advances research into
physical activity and AF from the ordinal to the numeric: quantifying
activity, even if only over a week, clearly provides more reliable and
quantifiable information than asking participants about their activity
levels. Understanding the optimal dose and pattern of physical activity
will be advanced substantially by such quantification. Fortunately,
quantifiable estimation of activity is now readily available via wearable
devices.
The findings of the report by Khurshid and colleagues fit into the
emerging U-shaped relationship between physical activity and AF
risk. The extremes of little or no physical activity as well as high levels
of activity are not well represented in the UK Biobank. Nonetheless,
a mild increase of AF risk at the lower and upper tails can be seen in
this cohort.9 The UK Biobank enrolled middle-aged men and women,
and is thus not very likely to include many competitive athletes.
Studies using objectively measured physical activity in physically active
populations such as athletes are thus desirable to determine the tip-
ping point where vigorous exercise offsets the beneficial effects on
other AF risk factors. In addition, despite adjustment for AF risk fac-
tors, the mechanisms by which exercise reduces the risk of incident
AF remain unknown. General effects on cardiovascular health com-
pete with atrial-specific effects. This may in the future be addressed
by research into quantifiable cardiovascular biomodulators associ-
ated with AF, e.g. natriuretic peptides: these are increased in re-
sponse to acute aerobic exercise, probably reflecting atrial dilation,
but decrease after chronic aerobic endurance training, possibly due
to lower peripheral vascular resistance.10
From quantitative diagnostics to
mobile health interventions
The population-wide use of an accelerometer provides a glimpse
into future opportunities to estimate and alter health-modifying be-
haviour. With >100 000 mobile health apps and >400 wearable activ-
ity monitors currently available,11 mobile technology offers new and
affordable possibilities for prevention and patient care. Integrating in-
formation from complementary biosensors increasingly allows fine-
tuning of lifestyle and risk factors in everyday life for risk optimization
through semi-continuous quantification, evaluation, and instantan-
eous, possibly motivational, feedback. Clearly, there is an urgent need
to evaluate the benefit and harm (e.g. overdiagnosis and overtreat-
ment, or anxiety based on misinterpretation of findings) of these
technologies in a cardiovascular context.
Whether mobile health applications can improve risk stratification
and timing of interventions such as starting oral anticoagulation, and
whether these tools can be used to inform populations about the
health impacts of their behaviour needs to be demonstrated in clinical
trials. An example for testing the use of mobile health monitoring is
the Smart in OAC case-finding study assessing the feasibility and effi-
cacy of a cloud-based analytical service in combination with a pulse
plethysmographic wristband in detecting absolute arrhythmia
(NCT04579159). The app will also be used to validate and enhance
clinical and risk factor information on the participants captured during
the monitoring period.
Thus, digital devices may provide simple, low-threshold access to
screening technology targeting at-risk populations and patients. They
can provide feedback on health behaviours and possibly help change
risk factor profiles and improve outcomes through optimized, more
continuous, and fast feedback loops (Graphical Abstract).
The study by Khurshid and the open access policy of the UK
Biobank illustrate how quantitative activity monitoring can benefit re-
search into AF. Their study broadens our thinking about mobile
health, and illustrates how much well-conducted clinical research is
needed to estimate the benefits and risks of mobile health-based
interventions. We need to encourage controlled trials of mobile
health and to continue a broad discussion about the ethical and judi-
cial rules for using such technology in societies deeply grounded in
freedom and human rights.
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